ResMed (RMD) Competitors $256.96 +1.08 (+0.42%) Closing price 07/3/2025 03:30 PM EasternExtended Trading$256.86 -0.10 (-0.04%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RMD vs. MEDP, EHC, HIMS, SYK, MDT, BDX, EW, IDXX, DXCM, and STEShould you be buying ResMed stock or one of its competitors? The main competitors of ResMed include Medpace (MEDP), Encompass Health (EHC), Hims & Hers Health (HIMS), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), DexCom (DXCM), and STERIS (STE). These companies are all part of the "medical" sector. ResMed vs. Its Competitors Medpace Encompass Health Hims & Hers Health Stryker Medtronic Becton, Dickinson and Company Edwards Lifesciences IDEXX Laboratories DexCom STERIS ResMed (NYSE:RMD) and Medpace (NASDAQ:MEDP) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership. Which has more volatility & risk, RMD or MEDP? ResMed has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Medpace has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Is RMD or MEDP more profitable? ResMed has a net margin of 26.15% compared to Medpace's net margin of 19.31%. Medpace's return on equity of 54.36% beat ResMed's return on equity.Company Net Margins Return on Equity Return on Assets ResMed26.15% 25.67% 18.59% Medpace 19.31%54.36%20.81% Does the media prefer RMD or MEDP? In the previous week, ResMed had 21 more articles in the media than Medpace. MarketBeat recorded 27 mentions for ResMed and 6 mentions for Medpace. ResMed's average media sentiment score of 1.37 beat Medpace's score of 0.88 indicating that ResMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 21 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, RMD or MEDP? ResMed has higher revenue and earnings than Medpace. Medpace is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioResMed$4.69B8.04$1.02B$8.9128.84Medpace$2.11B4.38$404.39M$13.1024.54 Do institutionals & insiders hold more shares of RMD or MEDP? 55.0% of ResMed shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 0.7% of ResMed shares are held by insiders. Comparatively, 20.3% of Medpace shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts rate RMD or MEDP? ResMed presently has a consensus target price of $259.33, indicating a potential upside of 0.92%. Medpace has a consensus target price of $344.82, indicating a potential upside of 7.25%. Given Medpace's higher probable upside, analysts clearly believe Medpace is more favorable than ResMed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ResMed 1 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.64Medpace 0 Sell rating(s) 11 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.21 SummaryResMed beats Medpace on 10 of the 17 factors compared between the two stocks. Get ResMed News Delivered to You Automatically Sign up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RMD vs. The Competition Export to ExcelMetricResMedMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$37.68B$10.52B$5.56B$20.72BDividend Yield0.83%2.07%5.24%3.72%P/E Ratio28.8417.0327.6128.07Price / Sales8.0429.54417.3038.44Price / Cash27.8522.9936.8922.53Price / Book7.763.668.034.58Net Income$1.02B$235.40M$3.18B$985.54M7 Day Performance0.76%2.15%2.93%2.79%1 Month Performance2.91%3.38%3.75%5.46%1 Year Performance31.90%-10.18%35.20%15.06% ResMed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RMDResMed4.6286 of 5 stars$256.96+0.4%$259.33+0.9%+35.7%$37.68B$4.69B28.849,980News CoveragePositive NewsInsider TradeMEDPMedpace4.4545 of 5 stars$313.86+1.0%$344.82+9.9%-20.2%$9.02B$2.16B23.965,900EHCEncompass Health4.8537 of 5 stars$122.60+0.3%$127.00+3.6%+38.4%$12.36B$5.37B25.3340,000News CoveragePositive NewsEx-DividendHIMSHims & Hers Health2.1767 of 5 stars$49.94+1.1%$39.58-20.7%+133.8%$11.18B$1.48B72.381,637Trending NewsInsider TradeSYKStryker4.5808 of 5 stars$395.71+0.8%$427.30+8.0%+18.1%$151.04B$23.22B53.4753,000Positive NewsMDTMedtronic4.8966 of 5 stars$87.25+1.4%$97.87+12.2%+14.7%$111.90B$33.54B24.1095,000Positive NewsBDXBecton, Dickinson and Company4.8513 of 5 stars$172.31+0.8%$219.22+27.2%-23.0%$49.39B$20.18B32.8877,000Positive NewsEWEdwards Lifesciences4.3465 of 5 stars$78.34+0.2%$80.20+2.4%-15.7%$45.95B$5.52B11.1917,300News CoveragePositive NewsIDXXIDEXX Laboratories3.842 of 5 stars$536.34+0.9%$546.00+1.8%+14.4%$43.13B$3.90B49.5710,800Positive NewsAnalyst ForecastDXCMDexCom4.9196 of 5 stars$87.29+1.1%$98.50+12.8%-25.4%$34.23B$4.03B65.147,600Positive NewsSTESTERIS4.9088 of 5 stars$240.03+0.5%$263.83+9.9%+9.3%$23.61B$5.46B38.7116,000Positive News Related Companies and Tools Related Companies Medpace Competitors Encompass Health Competitors Hims & Hers Health Competitors Stryker Competitors Medtronic Competitors Becton, Dickinson and Company Competitors Edwards Lifesciences Competitors IDEXX Laboratories Competitors DexCom Competitors STERIS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:RMD) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ResMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ResMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RMD Stock Alerts